Immunovant Inc Dossier
Qualitative Analysis
Business overview
Immunovant, Inc. is a clinical-stage immunology company dedicated to developing innovative, targeted therapies for people with autoimmune diseases. The company is a trailblazer in anti-FcRn (neonatal fragment crystallizable receptor) technology, focusing its development efforts on its lead asset, IMVT-1402. IMVT-1402 is a fully human monoclonal antibody designed to inhibit FcRn, thereby reducing levels of pathogenic immunoglobulin G (IgG) antibodies that drive various autoimmune conditions. Immunovant operates as a subsidiary of Roivant Sciences Ltd.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the Phase 3 trial failures of first-generation FcRn inhibitor batoclimab in thyroid eye disease (TED) in April 2026, Immunovant discontinued all further development of batoclimab to focus resources entirely on its next-generation, deep-suppression FcRn blocker, IMVT-1402.
Expected impact: Mitigates safety and efficacy risks associated with batoclimab while accelerating the development of a potentially best-in-class asset (IMVT-1402) across multiple high-value indications.
Developing IMVT-1402 across a broad spectrum of IgG-mediated autoimmune indications, including Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease (SjD), difficult-to-treat rheumatoid arthritis (D2T RA), and cutaneous lupus erythematosus (CLE).
Expected impact: Establishes a diversified, high-value immunology franchise targeting multiple indications with high unmet medical needs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Immunovant with the core intellectual property rights and exclusive licenses to develop, manufacture, and commercialize its lead clinical assets, including IMVT-1402 and batoclimab, in licensed territories.
Terms: Subject to upfront payments, development and regulatory milestones, and tiered royalties on net sales.
Roivant incubated Immunovant and remains its controlling shareholder, providing strategic oversight, clinical development collaboration, and financial backing, including leading a public offering that raised approximately $550 million in late 2025.
Terms: Roivant holds a majority ownership stake and participates in strategic financing rounds to support Immunovant's cash runway.